Successful treatment of portopulmonary hypertension with bosentan: Case report

European Journal of Clinical Investigation

Volumn 36, Issue SUPPL. 3, 2006, Pages 62-66

  Stahler G ^a   Von Hunnius, P ^a  

^a Klinik Lowenstein   (Germany)

Author keywords

Bosentan; Endothelin; Liver cirrhosis; Portal hypertension; Portopulmonary hypertension; Pulmonary arterial hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; EXERCISE; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS, ALCOHOLIC; MALE; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TREATMENT OUTCOME; VASODILATION;

EID: 33746855527     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01693.x     Document Type: Conference Paper

References (25)

1. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003;133:163-9.
2. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
3. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-66.
4. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.
5. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71:543-51.
6. Blendis L, Wong F. Portopulmonary hypertension: an increasingly important complication of cirrhosis. Gastroenterology 2003;125:622-4.
7. Gerbes A, Neuhofer W. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006;36(Suppl. 3):54-61.
8. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999;67:1087-93.
9. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004;10:174-82.
10. Kahler CM, Graziadei I, Wiedermann CJ, Kneussl MP, Vogel W. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000;112:637-40.
11. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-6.
12. Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004;24:703-7.
13. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-8.
14. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
15. Findlay JY, Plevak DJ, Krowka MJ, Sack EM, Porayko MK. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999;5:362-5.
16. Channick R, Badesch DB, Tapson VF, Simonneau G, Robbins I, Frost A et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant 2001;20:262-3.
17. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
18. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-9.
19. Denton C, Humbert M, Rubin L, Coghlan J, Black C. Dual endothelin receptor antagonism in pulmonary arterial hypertension related to systemic sclerosis. Eur J Clin Invest 2005;35:I72.
20. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43 (Suppl.): S62-7.
21. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004;2:1039-42.
22. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005;128:164-8.
23. Halank M, Miehlke S, Hoeffken G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004;77:1775-6.
24. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006;36(Suppl. 3):67-70.
25. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8.